Logo image of CRBP

CORBUS PHARMACEUTICALS HOLDI (CRBP) Stock Fundamental Analysis

NASDAQ:CRBP - Nasdaq - US21833P3010 - Common Stock - Currency: USD

7.79  +0.27 (+3.59%)

After market: 7.79 0 (0%)

Fundamental Rating

2

Overall CRBP gets a fundamental rating of 2 out of 10. We evaluated CRBP against 567 industry peers in the Biotechnology industry. CRBP has a great financial health rating, but its profitability evaluates not so good. CRBP is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

CRBP had negative earnings in the past year.
CRBP had a negative operating cash flow in the past year.
In the past 5 years CRBP always reported negative net income.
In the past 5 years CRBP always reported negative operating cash flow.
CRBP Yearly Net Income VS EBIT VS OCF VS FCFCRBP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

The Return On Assets of CRBP (-25.79%) is better than 71.02% of its industry peers.
CRBP has a better Return On Equity (-28.23%) than 79.33% of its industry peers.
Industry RankSector Rank
ROA -25.79%
ROE -28.23%
ROIC N/A
ROA(3y)-88.01%
ROA(5y)-103.66%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CRBP Yearly ROA, ROE, ROICCRBP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 -1K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CRBP so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CRBP Yearly Profit, Operating, Gross MarginsCRBP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 -2K -4K -6K

More info and screens

7

2. Health

2.1 Basic Checks

Compared to 1 year ago, CRBP has more shares outstanding
CRBP has more shares outstanding than it did 5 years ago.
CRBP has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CRBP Yearly Shares OutstandingCRBP Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
CRBP Yearly Total Debt VS Total AssetsCRBP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

Based on the Altman-Z score of -0.13, we must say that CRBP is in the distress zone and has some risk of bankruptcy.
CRBP has a Altman-Z score of -0.13. This is in the better half of the industry: CRBP outperforms 63.78% of its industry peers.
There is no outstanding debt for CRBP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -0.13
ROIC/WACCN/A
WACCN/A
CRBP Yearly LT Debt VS Equity VS FCFCRBP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M -100M

2.3 Liquidity

CRBP has a Current Ratio of 12.94. This indicates that CRBP is financially healthy and has no problem in meeting its short term obligations.
CRBP has a better Current ratio (12.94) than 86.40% of its industry peers.
A Quick Ratio of 12.94 indicates that CRBP has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 12.94, CRBP belongs to the top of the industry, outperforming 86.40% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 12.94
Quick Ratio 12.94
CRBP Yearly Current Assets VS Current LiabilitesCRBP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

0

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 63.94% over the past year.
EPS 1Y (TTM)63.94%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%56.91%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, CRBP will show a decrease in Earnings Per Share. The EPS will decrease by -9.04% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-44.39%
EPS Next 2Y-17.35%
EPS Next 3Y-18.96%
EPS Next 5Y-9.04%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CRBP Yearly Revenue VS EstimatesCRBP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M
CRBP Yearly EPS VS EstimatesCRBP Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -20 -40

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CRBP. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CRBP. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CRBP Price Earnings VS Forward Price EarningsCRBP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CRBP Per share dataCRBP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10

4.3 Compensation for Growth

A cheap valuation may be justified as CRBP's earnings are expected to decrease with -18.96% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-17.35%
EPS Next 3Y-18.96%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CRBP!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CORBUS PHARMACEUTICALS HOLDI

NASDAQ:CRBP (5/2/2025, 8:00:01 PM)

After market: 7.79 0 (0%)

7.79

+0.27 (+3.59%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-11 2025-03-11/bmo
Earnings (Next)05-05 2025-05-05
Inst Owners90.43%
Inst Owner Change0.02%
Ins Owners1.72%
Ins Owner Change1.57%
Market Cap95.27M
Analysts86.25
Price Target53.15 (582.28%)
Short Float %19.42%
Short Ratio9.3
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)10.57%
Min EPS beat(2)-18.43%
Max EPS beat(2)39.57%
EPS beat(4)3
Avg EPS beat(4)18.05%
Min EPS beat(4)-18.43%
Max EPS beat(4)39.57%
EPS beat(8)6
Avg EPS beat(8)16.62%
EPS beat(12)7
Avg EPS beat(12)1.2%
EPS beat(16)10
Avg EPS beat(16)6.97%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-8.22%
EPS NQ rev (1m)0.1%
EPS NQ rev (3m)11.85%
EPS NY rev (1m)0%
EPS NY rev (3m)0.2%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.67
P/tB 0.67
EV/EBITDA N/A
EPS(TTM)-3.66
EYN/A
EPS(NY)-5.28
Fwd EYN/A
FCF(TTM)-2.95
FCFYN/A
OCF(TTM)-2.95
OCFYN/A
SpS0
BVpS11.65
TBVpS11.65
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -25.79%
ROE -28.23%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-88.01%
ROA(5y)-103.66%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 12.94
Quick Ratio 12.94
Altman-Z -0.13
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)2.11%
Cap/Depr(5y)83.89%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)63.94%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%56.91%
EPS Next Y-44.39%
EPS Next 2Y-17.35%
EPS Next 3Y-18.96%
EPS Next 5Y-9.04%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-8.07%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5Y-15.19%
FCF growth 1Y3.86%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y3.83%
OCF growth 3YN/A
OCF growth 5YN/A